Search results for "Statin"

showing 10 items of 545 documents

Abstract 1778: Preclinical characterization of the safety and antitumor activity of IMAB027-vcMMAE, an anticlaudin 6 antibody-drug conjugate

2018

Abstract Background Claudin 6 (CLDN6) is a tight junction membrane protein whose expression in normal tissue is confined to embryonic cells, but is aberrantly expressed in various human cancers. The anti-CLDN6 monoclonal antibody (mAb), IMAB027, has shown promising antitumor activity in preclinical human CLDN6-positive (CLDN6+) cancer models. Conjugation of IMAB027 with monomethyl auristatin E (MMAE) may utilize the precision tumor-targeting of the mAb to deliver a highly effective cytotoxic drug to the tumor. In this report we present the preclinical characterization of this antibody–drug conjugate, IMAB027–vcMMAE. Methods Internalization of IMAB027 in various CLDN6+ human ovarian (OC) and…

Cancer Researchmedicine.diagnostic_testFlow cytometrychemistry.chemical_compoundOncologyMonomethyl auristatin EchemistryIn vivoCell cultureApoptosismedicineCancer researchCytotoxic T cellViability assayCytotoxicityCancer Research
researchProduct

Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast canc…

2015

Raf-1 kinase inhibitor protein (RKIP) is a tumor suppressor and metastasis inhibitor, which enhances drug-induced apoptosis of cancer cells. Downregulation of RKIP may be significant in the biology of highly aggressive and drug-resistant tumors, for example triple-negative breast cancers (TNBCs). Potential causes for the low levels of RKIP expressed by SUM 159 TNBC cells were investigated in the present study. Bisulphite modification, methylation specific-polymerase chain reaction (PCR) and a TransAM NF-κB assay were performed and the results suggested that various mechanisms, including methylation of the gene promoter, histone deacetylation and nuclear factor-κB (NF-κB) activation, but not…

Cancer Researchmedicine.drug_classCell growthtriple-negative breast cancer Raf-1 kinase inhibitor protein epigenetic changes microRNA-224 nuclear factor-κBHistone deacetylase inhibitorArticlesCell cycleBiologyMolecular biologyDemethylating agentchemistry.chemical_compoundTrichostatin AOncologychemistryCancer cellmedicineCancer researchGrowth inhibitionTranscription factormedicine.drug
researchProduct

A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) …

2013

4031 Background: The novel somatostatin analog (SSA) pasireotide has a broader binding profile than currently available SSA (octreotide and lanreotide). Results from a phase III study (NCT00690430) of pasireotide LAR (P) vs octreotide LAR (O) in patients (pts) with NET and disease-related symptoms uncontrolled by the maximum approved dose of available SSA are shown. Methods: Pts (N=110) were randomized and stratified by predominant symptom at baseline (diarrhea [D], flushing [F], or D+F) 1:1 to P (60 mg IM) or O (40 mg IM) q28d. Primary objective was symptom response at month (M) 6. Secondary objectives included tumor response and safety. Progression-free survival (PFS) was an exploratory …

Cancer Researchmedicine.medical_specialtybusiness.industryOctreotideDiseaseNeuroendocrine tumorsmedicine.diseaseLanreotideOctreotide larGastroenterologyPasireotidechemistry.chemical_compoundSomatostatinEndocrinologyOncologychemistryInternal medicineMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

2019

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supp…

Cancer Researchmedicine.medical_specialtypositron emission tomographymedicine.medical_treatmentReviewlcsh:RC254-282meningioma030218 nuclear medicine & medical imagingMeningioma03 medical and health sciences0302 clinical medicineNeuroimagingFunctional neuroimagingmedicineotorhinolaryngologic diseasesMedical diagnosisRadiation treatment planningGrading (tumors)neoplasmsMeningioma; Neuroimaging; Positron emission tomography; Radionuclide therapy; Somatostatin receptorneuroimagingbusiness.industryradionuclide therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasesomatostatin receptorOncologymeningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy030220 oncology & carcinogenesisRadionuclide therapyRadiologybusinessWatchful waitingCancers
researchProduct

Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?

2013

ISSN 1758-4299 10.2217/CLP.13.29 © 2013 Future Medicine Ltd Clin. Lipidol. (2013) 8(3), 273–277 Pleiotropic effects of statins Millions of patients worldwide are currently tak­ ing prescribed statins. Clinical trials have dem­ onstrated that statins reduce the risk of cardio­ vascular disease [1]. Statins are well known to reduce cholesterol levels through the inhibition of 3­hydroxy­methylglutaryl CoA reductase [2]. However, great interest has recently been paid to the mechanisms beyond cholesterol reduc­ tion (pleiotropic effects) by which statins exert their action. Indeed, statins are associated with plaque stabilization and improvement of endo­ thelial function, as well as anti­inflamm…

Cancer preventionIsoprenoid synthesisbusiness.industryCholesterolEndocrinology Diabetes and Metabolismnutritional and metabolic diseasesContext (language use)Pharmacologyanticancer drugs cancer chemotherapeutics statins tumorchemistry.chemical_compoundchemistryAntithromboticMedicinelipids (amino acids peptides and proteins)cardiovascular diseasesCardiology and Cardiovascular MedicinebusinessClinical Lipidology
researchProduct

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardioto…

2015

Although treatment for heart failure induced by cancer therapy has improved in recent years, the prevalence of cardiomyopathy due to antineoplastic therapy remains significant worldwide. In addition to traditional mediators of myocardial damage, such as reactive oxygen species, new pathways and target cells should be considered responsible for the impairment of cardiac function during anticancer treatment. Accordingly, there is a need to develop novel therapeutic strategies to protect the heart from pharmacologic injury, and improve clinical outcomes in cancer patients. The development of novel protective therapies requires testing putative therapeutic strategies in appropriate animal model…

Cardiac function curveACE inhibitorsCardiotonic AgentsNeuregulin-1CardiomyopathyAntineoplastic AgentsPreclinical modelsCardioprotectionCardiotonic AgentsPharmacologyBioinformaticsmedicine.disease_causeCancer therapy-induced cardiac injury ;Preclinical modelsMitochondria HeartBeta-blockersNeoplasmsCancer therapy-induced cardiac injuryMedicineAnimalsHumansCardiac stem cellsCardioprotectionCardiotoxicityACE inhibitors; Beta-blockers; Cancer therapy-induced cardiac injury; Cardiac stem cells; Cardioprotection; Mitochondria; Neuregulin-1; Oxidative stress; Preclinical models; Statinsbusiness.industryStatinsCancermedicine.diseaseCardiotoxicityMitochondriaCancer therapy-induced cardiac injury Preclinical models Cardioprotection Mitochondria Neuregulin-1 Oxidative stress Statins Beta-blockers ACE inhibitors Cardiac stem cellsDisease Models AnimalOxidative StressHeart failureCardiology and Cardiovascular MedicinebusinessOxidative stress
researchProduct

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardio…

2013

Background: We assessed the influence of atorvastatin on selected indicators of an inflammatory condition, left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy (DCM). Methods. We included 68 DCM patients with left ventricular ejection fraction (LVEF) ≤40% treated optimally in a prospective, randomized study. They were observed for 5 years. Patients were divided into two groups: patients who were commenced on atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A), and patients who were treated according to current recommendations without statin therapy (group B). Results: After 5-year follow-u…

Cardiomyopathy DilatedMalemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryDiastoleCardiomyopathyDilated cardiomyopathyHemodynamicsHeart failureAtorvastatin Dilated cardiomyopathy Heart failure InflammationVentricular Function LeftEndocrinologyInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesAgedBiochemistry medicalInflammationEjection fractionbusiness.industryResearchBiochemistry (medical)Anti-Inflammatory Agents Non-SteroidalDilated cardiomyopathyMiddle Agedmedicine.diseaseUric AcidHospitalizationHeptanoic AcidsHeart failureCardiologyCytokinesFemalebusinessmedicine.drugFollow-Up StudiesLipids in health and disease
researchProduct

Impact of infectious burden on progression of carotid atherosclerosis.

2002

Background and Purpose— Recent findings suggest a causative role of infections in the pathogenesis of atherosclerosis. The extent of atherosclerosis and the prognosis of patients with atherosclerosis seem to be increased by the number of infections to which an individual has been exposed. In a prospective study, we evaluated the effect of 8 pathogens and the aggregate pathogen burden on the progression of carotid atherosclerosis. Methods— In 504 patients (74.9% men; age, 62.9±10 years), we measured intima-media thickness and prevalence of carotid artery stenosis. Follow-up measurements after a mean of 2.5 years were available in 427 patients (85%). Blood samples were taken, and IgG or IgA …

Carotid Artery DiseasesMalemedicine.medical_specialtyMycoplasma pneumoniaePathologyEpstein-Barr Virus InfectionsStatinHaemophilus Infectionsmedicine.drug_classComorbiditymedicine.disease_causeAntibodies ViralInfectionsGastroenterologyVirusHelicobacter InfectionsSeroepidemiologic StudiesInternal medicineGermanymedicineOdds RatioPrevalenceHumansMycoplasma InfectionsProspective StudiesProspective cohort studyChlamydophila InfectionsUltrasonographyAdvanced and Specialized NursingChlamydiaVascular diseasebusiness.industryHerpes SimplexOdds ratioMiddle Agedmedicine.diseaseAntibodies BacterialImmunoglobulin AHerpes simplex virusCarotid ArteriesImmunoglobulin GCytomegalovirus InfectionsDisease ProgressionFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessTunica IntimaTunica MediaStroke
researchProduct

Fetuin-A and Cystatin C Are Endogenous Inhibitors of Human Meprin Metalloproteases

2010

Meprin α and β, zinc metalloproteinases, play significant roles in inflammation, including inflammatory bowel disease (IBD), possibly by activating cytokines, like interleukin 1β, interleukin 18, or tumor growth factor α. Although a number of potential activators for meprins are known, no endogenous inhibitors have been identified. In this work, we analyzed the inhibitory potential of human plasma and identified bovine fetuin-A as an endogenous meprin inhibitor with a K(i) (inhibition constant) of 4.2 × 10(-5) M for meprin α and a K(i) of 1.1 × 10(-6) M meprin β. This correlated with data obtained for a fetuin-A homologue from carp (nephrosin inhibitor) that revealed a potent meprin α and β…

Carpsalpha-2-HS-GlycoproteinMolecular Sequence DataMatrix metalloproteinaseBiochemistryPlasma03 medical and health sciencesmedicineAnimalsHumansAmino Acid SequenceCystatin C030304 developmental biology0303 health sciencesMetalloproteinasebiology030302 biochemistry & molecular biologyProteolytic enzymesMetalloendopeptidasesBlood ProteinsTrypsinFetuinProtease inhibitor (biology)3. Good healthBiochemistryCystatin Cbiology.proteinCattleCystatinSequence Alignmentmedicine.drugBiochemistry
researchProduct

Properties of the yeast nuclear histone deacetylase.

1994

A nuclear histone deacetylase from yeast was partially purified and some of its characteristics were studied. Histone deacetylase activity was stimulated in vitro by high-mobility-group nonhistone chromatin proteins 1 and 2 and ubiquitin and inhibited by spermine and spermidine, whereas n-butyrate had no significant inhibitory effect. Like the mammalian enzyme, partially purified histone deacetylase from yeast was strongly inhibited by trichostatin A. However, in crude extract preparations the yeast enzyme was not inhibited and treatment with trichostatin in vivo did not show any effect, either on the histone acetylation level or on cell viability. At low ionic strength, the enzyme can be i…

Cell NucleusHistone deacetylase 5HDAC11ChemistryHistone deacetylase 2HDAC10Cell BiologySaccharomyces cerevisiaeHydroxamic AcidsBiochemistryHistone DeacetylasesSubstrate SpecificityHistone Deacetylase InhibitorsMolecular WeightTrichostatin ABiochemistrymedicineChromatography GelHistone deacetylase activityHistone deacetylaseMolecular Biologymedicine.drugDeacetylase activityResearch ArticleThe Biochemical journal
researchProduct